Published TCIMAIL newest issue No.201
Maximum quantity allowed is 999
CAS RN: 54965-24-1 | Product Number: T2510
Tamoxifen Citrate
Purity: >98.0%(T)(HPLC)
- (Z)-1-(4-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene Citrate
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | T2510 |
Purity / Analysis Method
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__6H__2__9NO·C__6H__8O__7 = 563.65 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Light Sensitive,Hygroscopic,Heat Sensitive |
Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 54965-24-1 |
Related CAS RN
|
10540-29-1 |
| Reaxys Registry Number | 8888650 |
| PubChem Substance ID | 87560062 |
| Merck Index (14) | 9048 |
| MDL Number | MFCD00058321 |
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting Point | 142 °C(dec.) |
| Solubility in water | Slightly soluble |
| Solubility (soluble in) | Methanol, Acetone, Ethanol |
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H302 : Harmful if swallowed. H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. H350 : May cause cancer. |
| Precautionary Statements | P263 : Avoid contact during pregnancy and while nursing. P260 : Do not breathe dust. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. |
| EC Number | 259-415-2 |
| RTECS# | KH2387000 |
| HS Number | 2922190090 |
References
- Tamoxifen in the treatment of breast cancer
- Tamoxifen, raloxifene, and the prevention of breast cancer
- Mechanisms of tamoxifen-induced apoptosis
- Mechanisms of tamoxifen resistance
- CYP2D6 and tamoxifen: DNA matters in breast cancer
References
- Tamoxifen in the treatment of breast cancer
- Tamoxifen, Raloxifene, and the Prevention of Breast Cancer
- Mechanisms of tamoxifen-induced apoptosis
- Mechanisms of tamoxifen resistance
- CYP2D6 and tamoxifen: DNA matters in breast cancer
Documents
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.